Low-Dose Tissue Plasminogen Activator for Calciphylaxis
Authors:
- Roger H. WeenigRWRoger H. Weenig
- Mark D. P. DavisMDMark D. P. Davis
- Marian T. McEvoyMMMarian T. McEvoy
- Mark R. PittelkowMPMark R. Pittelkow
- 1 September 2004
- journal article
- case report
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 140 (9) , 1045-1048
Abstract
Case Report from JAMA Dermatology — Low-Dose Tissue Plasminogen Activator for CalciphylaxisKeywords
This publication has 16 references indexed in Scilit:
- Calciphylaxis in a Patient with Rheumatoid Arthritis without Renal Failure and Hyperparathyroidism: The Possible Role of Long-Term Steroid Use and Protein S DeficiencyClinical Rheumatology, 2002
- Hyperbaric oxygen in the treatment of calciphylaxis: a case seriesNephrology Dialysis Transplantation, 2001
- Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidismSurgery, 2001
- New directions in thrombolytic therapyCurrent Opinion in Pharmacology, 2001
- Is calciphylaxis best treated surgically or medically?Surgery, 2000
- Calcified subcutaneous arterioles with infarcts of the subcutis and skin (“calciphylaxis”) in chronic renal failureAmerican Journal of Kidney Diseases, 2000
- Cutaneous necrosis from calcific uremic arteriolopathyAmerican Journal of Kidney Diseases, 1998
- The vascular calcification-cutaneous necrosis syndromeJournal of the American Academy of Dermatology, 1995
- Tissue Plasminogen Activator for Treatment of Livedoid VasculitisMayo Clinic Proceedings, 1992
- Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxisThe American Journal of Medicine, 1990